Other languages Kaleido Biosciences, Inc.

Equities

KLDO

US4833471000

Market Closed - OTC Markets Other stock markets 09:47:01 2024-04-26 am EDT			5-day change	1st Jan Change
0.0001 ^USD	0.00%		0.00%	+9,900.00%

2022	Kaleido Biosciences, Inc.(NasdaqGS:KLDO) dropped from S&P Global BMI Index	CI
2022	Kaleido Biosciences, Inc.(NasdaqGS:KLDO) dropped from S&P TMI Index	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kaleido Biosciences, Inc. Announces Cessation of All of the Company’s Ongoing Operations	22-04-08
Kaleido Biosciences, Inc. Announces Management Changes	22-04-08
Kaleido Biosciences Initiated Process to Explore Strategic Alternatives	22-04-04
Kaleido Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-01
Kaleido Biosciences, Inc. Auditor Raises 'Going Concern' Doubt	22-03-31
Kaleido Biosciences, Inc. Announces Board Resignations	22-03-17
Radius Health Names New CFO	22-03-16
History shows stocks can weather rate hike cycle	22-03-16
Kaleido Biosciences, Inc. Announces Resignation of Jerald Korn, the General Counsel and Chief Operating Officer, Effective March 18, 2022	22-03-09
Kaleido Biosciences Halts Phase 2 Study on Chronic Obstructive Pulmonary Disease	22-01-31
Kaleido Biosciences, Inc. Decides Halt Work on a Planned Phase 2 Chronic Obstructive Pulmonary Disease Study	22-01-28
Kaleido Reports Findings From Study Data of Proposed Inflammatory Bowel Disease Treatment	22-01-21
Kaleido Biosciences Expands and Extends Collaboration With Janssen	21-12-06
Kaleido Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-01
Kaleido Biosciences, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2021	21-08-11
Kaleido Biosciences : Teams Up With COPD Foundation to Advance KB109 into Phase 2a Clinical Study	21-08-10
Kaleido Biosciences : Appoints Jerald Korn Chief Operating Officer	21-07-02
Kaleido Biosciences' : Q1 Loss Narrows; Expects Enough Funds to Operate Into Q1 2022	21-05-04
Kaleido Biosciences, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2021	21-05-04
Kaleido Biosciences : to Collaborate with MD Anderson Cancer Center Expert on Microbiome Therapies to Aid Stem Cell Transplantation	21-04-20

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Kaleido Biosciences, Inc.

Equities

KLDO

US4833471000

Other languages

Filters